The Thomson Group

The Thomson Group


Dr Emma Thomson

  • Clinical Senior Lecturer (Centre for Virus Research)
  • CLINICAL SENIOR LECTURER (School of Medicine, Dentistry and Nursing)

telephone: 01413302928
email: Emma.Thomson@glasgow.ac.uk

Research interests

CVR logo

‌Acute HCV UK: Acute hepatitis C virus (HCV) infection is an emerging infection in men who have sex with men (MSM) in Europe, the USA and Australia. While many studies have investigated the pathogenesis of infection during the chronic phase, very few have concentrated on virus evolution and the immune response during early (acute) infection. This is because the majority of patients remain asymptomatic until they have developed chronic infection and often present to medical attention only when they have serious liver disease (cirrhosis and hepatocellular carcinoma). Studies of the immune response during early infection are a critical component of the search for an effective vaccine – while major steps forward have been taken in the development of curative treatments for HCV, cost may limit their availability, especially in low and middle income countries.

Image of a flow diagram taken from a publication

My laboratory focusses on investigation of the mechanisms behind spontaneous clearance (up to 50% of infected individuals clear the virus without treatment) in order to advance the search for an effective HCV vaccine. We follow a cohort of 200 patients in Glasgow and London who have been identified with early infection and who have been recruited and followed-up regularly following diagnosis. We aim to identify novel B and T cell epitopes recognised during acute HCV infection using next-generation sequencing of the entire genome and functional assays including flow cytometry, ELISpots, neutralisation assays and replicon systems. This project is funded by the Wellcome Trust.

Image of a chimpanzee in a forest in Uganda. Photograph taken by Dr Emma ThomsonNew and emerging viral infections in Africa: Emerging viral infections are an ever-present threat to human and animal health and have often emerged from sub-Saharan Africa. The risk of transmission of viruses to previously unexposed populations has increased as a result of increased global travel, global warming and changes in our ecosystem and human behaviour. In the last 100 years, the emergence of HIV has resulted in at least 35 million deaths while more recently, Zika virus and Ebola virus caused health crises requiring major local and international interventions. Other viral infections (including unidentified infections) remain an unquantified threat to human and animal health. In order to address these risks effectively, major efforts need to be made to improve the infrastructure for identifying risks, developing treatments and vaccines and implementing these interventions in real time.

Image of a monkey sitting in a tree in a forest in Uganda. Photograph taken by Dr Emma ThomsonA vital tool used to detect potential threats in human, animal and environmental samples is next generation sequencing (NGS). We are currently using NGS to detect new and emerging viruses in East and West Africa (Uganda and The Gambia) in febrile undiagnosed patients. We are also engaged in improving local diagnostic capacity in the MRC centres in these countries so that undiagnosed new or emerging infections may be detected at source in the future, allowing more rapid control interventions. The CVR provided diagnostic support for the UK response to the Ebola virus outbreak in Sierra Leone (Dr Davis from my laboratory) and we were also involved in local real-time sequencing of EBOV from an infected patient with disease recurrence in Glasgow. These emerging viral infection projects are funded by the MRC and by the Scottish Research Council.

Clinical role: I work as an infectious diseases and general (internal) medicine consultant with specialist interests in early hepatitis C infection, HCV drug resistance and hepatitis C and HIV co-infection at the Queen Elizabeth University Hospital in Glasgow and have experience looking after patients with a wide range of infectious diseases. I am a member of the British HIV Association Hepatitis Sub-committee and work as an external consultant for the World Health Organisation. I have served on the Guidelines Development Group (GDG) for the WHO Guidelines for the Care, Screening and Treatment of Hepatitis C since 2015 and wrote the first draft of the guidelines in 2014.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Quinquennial Core Funds
    Medical Research Council
    2016 - 2021
     
  • Is the Ugandan Population Vulnerable to a Zika Virus Epidemic?
    Medical Research Council
    2016 - 2017
     
  • T-cell mediated evolution of hepatitis C virus during acute infection
    Wellcome Trust
    2014 - 2018
     
  • Stratified medicine to Optimise the Treatment with Hepatitis C Virus Infection (STOP-HCV)
    Medical Research Council
    2013 - 2018
     
  • Relapse after treatment for acute HCV infection in HIV-positive men; viral recrudescence or reinfection?
    British HIV Association
    2011 - 2013
     

Publications

List by: Type | Date

Jump to: 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003
Number of items: 29.

2016

Thomson, E. et al. (2016) Comparison of next generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes. Journal of Clinical Microbiology, 54(10), pp. 2470-2484. (doi:10.1128/JCM.00330-16) (PMID:27385709) (PMCID:PMC5035407)

Jacobs, M. et al. (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet, 388(10043), pp. 498-503. (doi:10.1016/S0140-6736(16)30386-5) (PMID:27209148) (PMCID:PMC4967715)

Martin, N. K. et al. (2016) Can HCV direct-acting antiviral treatment as prevention reverse the HCV epidemic amongst men who have sex with men in the UK - epidemiological and modelling insights. Clinical Infectious Diseases, 62(9), pp. 1072-1080. (doi:10.1093/cid/ciw075) (PMID:26908813) (PMCID:PMC4826456)

Swann, R. E., Cowton, V. M., Robinson, M. W., Cole, S. J., Barclay, S. T., Mills, P. R., Thomson, E. c., McLauchlan, J. and Patel, A. (2016) Broad anti-hepatitis C virus (HCV) antibody responses are associated with improved clinical disease parameters in chronic HCV infection. Journal of Virology, 90(9), pp. 4530-4543. (doi:10.1128/JVI.02669-15) (PMID:26912610) (PMCID:PMC4836347)

Robinson, M. W., Hughes, J., Wilkie, G. S., Swann, R., Barclay, S. T., Mills, P. R., Patel, A. H., Thomson, E. C. and McLauchlan, J. (2016) Tracking TCRß sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region. Frontiers in Immunology, 7, 131. (doi:10.3389/fimmu.2016.00131) (PMID:27092143) (PMCID:PMC4820669)

Padam, P., Clark, S., Irving, W., Gellissen, R., Thomson, E., Main, J. and Cooke, G.S. (2016) Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease. Journal of Viral Hepatitis, 23(2), pp. 123-129. (doi:10.1111/jvh.12484) (PMID:26511293) (PMCID:PMC4924594)

Martin, F., Lee, J., Thomson, E., Tarrant, N., Hale, A. and Lacey, C. J. (2016) Two cases of possible transmitted drug resistant HIV virus: likely HIV superinfection and unmasking of pre-existing resistance. International Journal of STD and AIDS, 27(1), pp. 66-69. (doi:10.1177/0956462415571671) (PMID:25663247) (PMCID:PMC4674743)

2015

Gaunt, E., Harvala, H., Osterback, R., Sreenu, V. B., Thomson, E., Waris, M. and Simmonds, P. (2015) Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. Journal of General Virology, 96(5), pp. 1067-1079. (doi:10.1099/vir.0.000062) (PMID:25614593) (PMCID:PMC4631059)

Abdelrahman, T., Hughes, J., Main, J., McLauchlan, J., Thursz, M. and Thomson, E. (2015) Reply. Hepatology, 61(4), p. 1438. (doi:10.1002/hep.27393) (PMID:25147121) (PMCID:PMC4407921)

Ardelrahman, T., Hughes, J., Main, J., McLauchlan, J., Thursz, M. and Thomson, E. (2015) Waiting time and transplantation for hepatocellular cancer: a balance between tempus fugit and carpe diem. Hepatology, 61(4), pp. 1438-1439. (doi:10.1002/hep.27434)

Shepherd, S. J., Abdelrahman, T., MacLean, A. R., Thomson, E. C., Aitken, C. and Gunson, R. N. (2015) Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. Journal of Clinical Virology, 65, pp. 50-53. (doi:10.1016/j.jcv.2015.02.005) (PMID:25766988)

Abdelrahman, T., Hughes, J., Main, J., McLauchlan, J., Thursz, M. and Thomson, E. (2015) Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment. Hepatology, 61(1), pp. 88-97. (doi:10.1002/hep.27192) (PMID:24797101) (PMCID:PMC4303934)

2014

McNaughton, A.L., Thomson, E.C., Templeton, K., Gunson, R.N. and McWilliam Leitch, E.C. (2014) Mixed genotype hepatitis C infections and implications for treatment. Hepatology, 59(3), p. 1209. (doi:10.1002/hep.26544) (PMID:23744801) (PMCID:PMC4296219)

2013

Leggewie, M., Sreenu, V. B., Abdelrahman, T., Leitch, E. C., Wilkie, G., Klymenko, T., Muir, D., Thursz, M., Main, J. and Thomson, E.C. (2013) Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS, 27(15), pp. 2485-2488. (doi:10.1097/QAD.0b013e328363b1f9) (PMID:23770494)

2011

Thomson, E.C., Smith, J.A. and Klenerman, P. (2011) The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. Journal of General Virology, 92(10), pp. 2227-2236. (doi:10.1099/vir.0.033910-0)

Thomson, E.C., Fleming, V.M., Main, J., Klenerman, P., Weber, J., Eliahoo, J., Smith, J., McClure, M.O. and Karayiannis, P. (2011) Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut, 60(6), pp. 837-845. (doi:10.1136/gut.2010.217166)

2010

Huang, K.-H.G. et al. (2010) B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nature Communications, 1, p. 102. (doi:10.1038/ncomms1100)

Smith, J.A., Aberle, J.H., Fleming, V.M., Ferenci, P., Thomson, E.C., Karayiannis, P., McLean, A.R., Holzmann, H. and Klenerman, P. (2010) Dynamic coinfection with multiple viral subtypes in acute hepatitis C. Journal of Infectious Diseases, 202(12), pp. 1770-1779. (doi:10.1086/657317)

Winston, A. et al. (2010) Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? Journal of Viral Hepatitis, 17(6), pp. 419-426. (doi:10.1111/j.1365-2893.2009.01198.x)

2009

Thomson, E.C., Nastouli, E., Main, J., Karayiannis, P., Eliahoo, J., Muir, D. and McClure, M.O. (2009) Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS, 23(1), pp. 89-93. (doi:10.1097/QAD.0b013e32831940a3)

Nastouli, E., Thomson, E.C., Karayiannis, P., Main, J., McClure, M. and Muir, D. (2009) Diagnosing acute hepatitis C in HIV-infected patients: nucleic acid testing compared with antibody and antigen-antibody detecting methods. Journal of Clinical Virology, 44(1), pp. 78-80. (doi:10.1016/j.jcv.2008.09.008)

2008

Fox, J., Nastouli, E., Thomson, E.C., Muir, D., McClure, M., Weber, J. and Fidler, S. (2008) Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS, 22(5), pp. 666-668. (doi:10.1097/QAD.0b013e3282f5f4cf)

Thomson, E.C. and Main, J. (2008) Epidemiology of hepatitis C virus infection in HIV-infected individuals. Journal of Viral Hepatitis, 15(11), pp. 773-781. (doi:10.1111/j.1365-2893.2008.00981.x)

2007

Garvey, L., Thomson, E.C., Main, J. and Winston, A. (2007) Response to "Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment". JAIDS: Journal of Acquired Immune Deficiency Syndromes, 46(5), pp. 656-657. (doi:10.1097/QAI.0b013e318157b0c8)

Garvey, L.J., Thomson, E.C., Lloyd, J., Cooke, G.S., Goldin, R.D. and Main, J. (2007) Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS, 21(11), pp. 1494-1495. (doi:10.1097/QAD.0b013e3281e7ed64)

2006

Bloom, C., Thomson, E.C. and Main, J. (2006) An elderly lady with sudden blindness and a sore foot. Journal of Infection, 52(2), e53-e54. (doi:10.1016/j.jinf.2005.05.002)

Garvey, L., Thomson, E.C. and Taylor, G.P. (2006) Progressive multifocal leukoencephalopathy: prolonged survival in patients treated with protease inhibitors and cidofovir: a case series. AIDS, 20(5), pp. 791-793. (doi:10.1097/01.aids.0000216390.83351.87)

2004

Thomson, E.C. and Main, J. (2004) Advances in hepatitis B and C. Current Opinion in Infectious Diseases, 17(5), pp. 449-459.

2003

Thomson, E.C. and Lynn, W.A. (2003) Septic thrombophlebitis with multiple pulmonary abscesses. Lancet Infectious Diseases, 3(2), p. 86. (doi:10.1016/S1473-3099(03)00516-4)

This list was generated on Wed May 24 15:36:37 2017 BST.
Jump to: Articles
Number of items: 29.

Articles

Thomson, E. et al. (2016) Comparison of next generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes. Journal of Clinical Microbiology, 54(10), pp. 2470-2484. (doi:10.1128/JCM.00330-16) (PMID:27385709) (PMCID:PMC5035407)

Jacobs, M. et al. (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet, 388(10043), pp. 498-503. (doi:10.1016/S0140-6736(16)30386-5) (PMID:27209148) (PMCID:PMC4967715)

Martin, N. K. et al. (2016) Can HCV direct-acting antiviral treatment as prevention reverse the HCV epidemic amongst men who have sex with men in the UK - epidemiological and modelling insights. Clinical Infectious Diseases, 62(9), pp. 1072-1080. (doi:10.1093/cid/ciw075) (PMID:26908813) (PMCID:PMC4826456)

Swann, R. E., Cowton, V. M., Robinson, M. W., Cole, S. J., Barclay, S. T., Mills, P. R., Thomson, E. c., McLauchlan, J. and Patel, A. (2016) Broad anti-hepatitis C virus (HCV) antibody responses are associated with improved clinical disease parameters in chronic HCV infection. Journal of Virology, 90(9), pp. 4530-4543. (doi:10.1128/JVI.02669-15) (PMID:26912610) (PMCID:PMC4836347)

Robinson, M. W., Hughes, J., Wilkie, G. S., Swann, R., Barclay, S. T., Mills, P. R., Patel, A. H., Thomson, E. C. and McLauchlan, J. (2016) Tracking TCRß sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region. Frontiers in Immunology, 7, 131. (doi:10.3389/fimmu.2016.00131) (PMID:27092143) (PMCID:PMC4820669)

Padam, P., Clark, S., Irving, W., Gellissen, R., Thomson, E., Main, J. and Cooke, G.S. (2016) Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease. Journal of Viral Hepatitis, 23(2), pp. 123-129. (doi:10.1111/jvh.12484) (PMID:26511293) (PMCID:PMC4924594)

Martin, F., Lee, J., Thomson, E., Tarrant, N., Hale, A. and Lacey, C. J. (2016) Two cases of possible transmitted drug resistant HIV virus: likely HIV superinfection and unmasking of pre-existing resistance. International Journal of STD and AIDS, 27(1), pp. 66-69. (doi:10.1177/0956462415571671) (PMID:25663247) (PMCID:PMC4674743)

Gaunt, E., Harvala, H., Osterback, R., Sreenu, V. B., Thomson, E., Waris, M. and Simmonds, P. (2015) Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. Journal of General Virology, 96(5), pp. 1067-1079. (doi:10.1099/vir.0.000062) (PMID:25614593) (PMCID:PMC4631059)

Abdelrahman, T., Hughes, J., Main, J., McLauchlan, J., Thursz, M. and Thomson, E. (2015) Reply. Hepatology, 61(4), p. 1438. (doi:10.1002/hep.27393) (PMID:25147121) (PMCID:PMC4407921)

Ardelrahman, T., Hughes, J., Main, J., McLauchlan, J., Thursz, M. and Thomson, E. (2015) Waiting time and transplantation for hepatocellular cancer: a balance between tempus fugit and carpe diem. Hepatology, 61(4), pp. 1438-1439. (doi:10.1002/hep.27434)

Shepherd, S. J., Abdelrahman, T., MacLean, A. R., Thomson, E. C., Aitken, C. and Gunson, R. N. (2015) Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. Journal of Clinical Virology, 65, pp. 50-53. (doi:10.1016/j.jcv.2015.02.005) (PMID:25766988)

Abdelrahman, T., Hughes, J., Main, J., McLauchlan, J., Thursz, M. and Thomson, E. (2015) Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment. Hepatology, 61(1), pp. 88-97. (doi:10.1002/hep.27192) (PMID:24797101) (PMCID:PMC4303934)

McNaughton, A.L., Thomson, E.C., Templeton, K., Gunson, R.N. and McWilliam Leitch, E.C. (2014) Mixed genotype hepatitis C infections and implications for treatment. Hepatology, 59(3), p. 1209. (doi:10.1002/hep.26544) (PMID:23744801) (PMCID:PMC4296219)

Leggewie, M., Sreenu, V. B., Abdelrahman, T., Leitch, E. C., Wilkie, G., Klymenko, T., Muir, D., Thursz, M., Main, J. and Thomson, E.C. (2013) Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS, 27(15), pp. 2485-2488. (doi:10.1097/QAD.0b013e328363b1f9) (PMID:23770494)

Thomson, E.C., Smith, J.A. and Klenerman, P. (2011) The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. Journal of General Virology, 92(10), pp. 2227-2236. (doi:10.1099/vir.0.033910-0)

Thomson, E.C., Fleming, V.M., Main, J., Klenerman, P., Weber, J., Eliahoo, J., Smith, J., McClure, M.O. and Karayiannis, P. (2011) Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut, 60(6), pp. 837-845. (doi:10.1136/gut.2010.217166)

Huang, K.-H.G. et al. (2010) B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nature Communications, 1, p. 102. (doi:10.1038/ncomms1100)

Smith, J.A., Aberle, J.H., Fleming, V.M., Ferenci, P., Thomson, E.C., Karayiannis, P., McLean, A.R., Holzmann, H. and Klenerman, P. (2010) Dynamic coinfection with multiple viral subtypes in acute hepatitis C. Journal of Infectious Diseases, 202(12), pp. 1770-1779. (doi:10.1086/657317)

Winston, A. et al. (2010) Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? Journal of Viral Hepatitis, 17(6), pp. 419-426. (doi:10.1111/j.1365-2893.2009.01198.x)

Thomson, E.C., Nastouli, E., Main, J., Karayiannis, P., Eliahoo, J., Muir, D. and McClure, M.O. (2009) Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS, 23(1), pp. 89-93. (doi:10.1097/QAD.0b013e32831940a3)

Nastouli, E., Thomson, E.C., Karayiannis, P., Main, J., McClure, M. and Muir, D. (2009) Diagnosing acute hepatitis C in HIV-infected patients: nucleic acid testing compared with antibody and antigen-antibody detecting methods. Journal of Clinical Virology, 44(1), pp. 78-80. (doi:10.1016/j.jcv.2008.09.008)

Fox, J., Nastouli, E., Thomson, E.C., Muir, D., McClure, M., Weber, J. and Fidler, S. (2008) Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS, 22(5), pp. 666-668. (doi:10.1097/QAD.0b013e3282f5f4cf)

Thomson, E.C. and Main, J. (2008) Epidemiology of hepatitis C virus infection in HIV-infected individuals. Journal of Viral Hepatitis, 15(11), pp. 773-781. (doi:10.1111/j.1365-2893.2008.00981.x)

Garvey, L., Thomson, E.C., Main, J. and Winston, A. (2007) Response to "Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment". JAIDS: Journal of Acquired Immune Deficiency Syndromes, 46(5), pp. 656-657. (doi:10.1097/QAI.0b013e318157b0c8)

Garvey, L.J., Thomson, E.C., Lloyd, J., Cooke, G.S., Goldin, R.D. and Main, J. (2007) Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS, 21(11), pp. 1494-1495. (doi:10.1097/QAD.0b013e3281e7ed64)

Bloom, C., Thomson, E.C. and Main, J. (2006) An elderly lady with sudden blindness and a sore foot. Journal of Infection, 52(2), e53-e54. (doi:10.1016/j.jinf.2005.05.002)

Garvey, L., Thomson, E.C. and Taylor, G.P. (2006) Progressive multifocal leukoencephalopathy: prolonged survival in patients treated with protease inhibitors and cidofovir: a case series. AIDS, 20(5), pp. 791-793. (doi:10.1097/01.aids.0000216390.83351.87)

Thomson, E.C. and Main, J. (2004) Advances in hepatitis B and C. Current Opinion in Infectious Diseases, 17(5), pp. 449-459.

Thomson, E.C. and Lynn, W.A. (2003) Septic thrombophlebitis with multiple pulmonary abscesses. Lancet Infectious Diseases, 3(2), p. 86. (doi:10.1016/S1473-3099(03)00516-4)

This list was generated on Wed May 24 15:36:37 2017 BST.

Research group members

Shirin Ashraf
Research Assistant

Chris Davis
Research Associate

Suleman Sabir
Research Assistant

Elizabeth Spence
Research Nurse

Weronika Witkowska
PhD student [email]

Marc Neibel
Research Technician [email]

Emma Thomson research

Research programmes: 

Acute hepatitis C virus (HCV) infection is an emerging infection in men who have sex with men (MSM) in Europe, the USA and Australia. While many studies have investigated the pathogenesis of infection during the chronic phase, very few have concentrated on virus evolution and the immune response during early (acute) infection. My laboratory focusses on investigation of the mechanisms behind spontaneous clearance (up to 50% of infected individuals clear the virus without treatment) in order to advance the search for an effective HCV vaccine using next-generation sequencing of the viral genome and functional B and T cell assays. 

Image of a flow diagram taken from a publication

Image of a monkey sitting in a tree in a forest in Uganda. Photograph taken by Dr Emma ThomsonEmerging viral infections are an ever-present threat to human and animal health and have often emerged from sub-Saharan Africa. The risk of transmission of viruses to previously unexposed populations has increased as a result of increased global travel, global warming and changes in our ecosystem and human behaviour. In the last 100 years, the emergence of HIV has resulted in at least 35 million deaths while more recently, Zika virus and Ebola virus caused health crises requiring major local and international interventions. Other viral infections (including unidentified infections) remain an unquantified threat to human and animal health. We are currently using NGS to detect new and emerging viruses in East and West Africa (Uganda and The Gambia) in febrile undiagnosed patients. We are also engaged in improving local diagnostic capacity in the MRC centres in these countries so that undiagnosed new or emerging infections may be detected at source in the future, allowing more rapid control interventions. 

Current research

Collaborators

CVR logo